Eric F. Medina

Abstract 2257: Eric Medina.

Eric F. Medina, Jacob I. Rodriguez, Alyssa Bujnak, Devon A. Lawson et autres

Abstract Most high-grade serous carcinomas are thought to originate from the fallopian tube epithelium and progress through pre-malignant states that are more susceptible to transformation in BRCA1/2 mutation carriers. However, the early epithelial and stromal programs that arise during transformation remain poorly …

us (code pays fourni par la source)

System analysis links SMARCD3 regulons to growth signaling and MEK inhibitor response in everolimus-resistant ER+ breast cancer cells

Eric F. Medina, Elena Farmaki, Jason I. Griffiths, Andrea H. Bild et autres

Estrogen receptor-positive breast cancer (ER+BC) accounts for ∼70% of all breast tumors, and 20%–40% of patients develop metastases. Everolimus is an mammalian target of rapamycin (mTOR) inhibitor used in combination with exemestane for metastatic ER+BC. However, resistance remains common and leads to …

us (code pays fourni par la source)

Blocking cancer-fibroblast mutualism inhibits proliferation of endocrine therapy resistant breast cancer

Jason I. Griffiths, Feng Chi, Elena Farmaki, Eric F. Medina et autres

Abstract In early-stage estrogen receptor-positive (ER + ) breast cancer, resistance to endocrine therapy (ET) and CDK4/6 inhibitors (CDK4/6i) often involve a shift away from estrogen-driven proliferation. The nature and source of compensatory growth signals driving cancer proliferation remain unknown but represent …

us (code pays fourni par la source)

Abstract 6383: Overcoming intrinsic mechanisms of cell cycle inhibitor resistance in estrogen receptor-positive (ER+) breast cancer

Kimya L Karimi, Jason I. Griffiths, Eric F. Medina, Elena Farmaki et autres

Abstract Estrogen receptor-positive breast cancer (ER+BC) represent about 70% of all breast cancer cases. Approximately 30-50% of ER+BCs eventually develop resistance to primary endocrine therapy and progress to metastatic disease. The addition of cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) to endocrine …

us (code pays fourni par la source)

Cellular interactions within the immune microenvironment underpins resistance to cell cycle inhibition in breast cancers

Jason I. Griffiths, Patrick A. Cosgrove, Eric F. Medina, Aritro Nath et autres

Immune evasion by cancer cells involves reshaping the tumor microenvironment (TME) via communication with non-malignant cells. However, resistance-promoting interactions during treatment remain lesser known. Here we examine the composition, communication, and phenotypes of tumor-associated cells in serial biopsies from stage II and …

us (code pays fourni par la source)

Abstract 6236: Systems biology modeling identifies SMARCD3 as a master regulator facilitating everolimus resistance in ER+ breast cancer

Eric F. Medina, Patrick A. Cosgrove, Εleni Farmaki, Vince Kornél Grolmusz et autres

Abstract Breast cancer is the most common malignancy in women and estrogen receptor positive (ER+) breast cancers represent nearly 75% of all breast tumors. Everolimus, an mTORC1 inhibitor, in combination with exemestane has been approved for patients with metastatic ER+ breast cancer. …

us (code pays fourni par la source)

Cell facilitation promotes growth and survival under drug pressure in breast cancer

Rena Emond, Jason I. Griffiths, Vince Kornél Grolmusz, Aritro Nath et autres

The interplay of positive and negative interactions between drug-sensitive and resistant cells influences the effectiveness of treatment in heterogeneous cancer cell populations. Here, we study interactions between estrogen receptor-positive breast cancer cell lineages that are sensitive and resistant to ribociclib-induced cyclin-dependent kinase …

us (code pays fourni par la source)

RAGE ablation attenuates glioma progression and enhances tumor immune responses by suppressing galectin-3 expression

Ian Y. Zhang, Shunan Liu, Leying Zhang, Rongrui Liang et autres

BACKGROUND: Malignant gliomas consist of heterogeneous cellular components that have adopted multiple overlapping escape mechanisms that overcome both targeted and immune-based therapies. The receptor for advanced glycation end products (RAGE) is a member of the immunoglobulin superfamily that is activated by diverse …

us, cn, hk (code pays fourni par la source)

IMMU-08. RAGE ABLATION ATTENUATES GLIOMA PROGRESSION AND ENHANCES TUMOR IMMUNE RESPONSES BY SUPPRESSING GALECTIN-3 EXPRESSION

Mojtaba Dayyani, Ian Zhang, Shunan Liu, Leying Zhang et autres

Abstract INTRODUCTION Malignant gliomas consist of heterogenous cellular components that have adopted multiple overlapping escape mechanisms that overcome both targeted and immune-based therapies. The receptor for advanced glycation end products (RAGE) is a member of the immunoglobulin superfamily that is activated by …

us, cn (code pays fourni par la source)

RAGE Inhibitors as Alternatives to Dexamethasone for Managing Cerebral Edema Following Brain Tumor Surgery

Shunan Liu, Yanyan Song, Ian Y. Zhang, Leying Zhang et autres

cn, us (code pays fourni par la source)

Tissue-Specific Transcriptomes Reveal Gene Expression Trajectories in Two Maturing Skin Epithelial Layers in Zebrafish Embryos

Shawn Cokus, Maricruz De La Torre, Eric F. Medina, Jeffrey P. Rasmussen et autres

Abstract Epithelial cells are the building blocks of many organs, including skin. The vertebrate skin initially consists of two epithelial layers, the outer periderm and inner basal cell layers, which have distinct properties, functions, and fates. The embryonic periderm ultimately disappears during …

us (code pays fourni par la source)